Viatris Inc. (VTRS) is a leading global healthcare provider based in Canonsburg, Pennsylvania, formed from the merger of Mylan and Pfizer's Upjohn division. The company operates with a diverse portfolio that includes generic, branded, and over-the-counter products, striving to enhance patient access to essential healthcare in over 165 countries. Viatris is focused on innovative solutions to address various health challenges while maintaining a commitment to cost-effectiveness and sustainability in the healthcare system. As it adapts to the changing industry landscape, Viatris is dedicated to improving patient outcomes and expanding global healthcare accessibility. Show more

Location: ROBERT J. COURY GLOBAL CENTER, CANONSBURG, PA, UNITED STATES, 15317, Canonsburg, PA, 15317, USA | Website: https://www.viatris.com | Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC | Sector: HEALTHCARE

Market Cap

15.11B

52 Wk Range

$6.60 - $13.68

Previous Close

$13.09

Open

$13.05

Volume

10,120,047

Day Range

$13.00 - $13.68

Enterprise Value

28.69B

Cash

975.3M

Avg Qtr Burn

N/A

Insider Ownership

0.28%

Institutional Own.

86.78%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
TYRVAYA (OC-01) (Varenicline) Details Dry eye disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Octreotide Acetate (Somatostatin Analog) Details Acromegaly And Neuroendocrine Tumor-Related Diarrhea	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Low Dose Estrogen Weekly Patch (Transdermal Contraceptive) Details Contraception	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pitolisant (Histamine H3 Antagonist) Details Obstructive Sleep Apnea Syndrome	NDA Acceptance for review	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pitolisant (Histamine H3 Antagonist) Details Narcolepsy	NDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Meloxicam (MR-107A-02) Details Moderate-to-severe acute surgical pain	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MR-141 (phentolamine ophthalmic solution 0.75%) Details Presbyopia	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MR-142 (phentolamine ophthalmic solution 0.75%) Details Keratorefractive patients with reduced mesopic vision	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MR-139 Details Blepharitis	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OC-01 (Varenicline) Details Neurotrophic Keratopathy	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MR-146 (AAV Gene Therapy) Details Neurotrophic Keratopathy	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.